
Larissa Haertle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4276298/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epigenetic signatures of gestational diabetes mellitus on cord blood methylation. Clinical Epigenetics, 2017, 9, 28.	1.8	85
2	IKZF1/3 and CRL4 ^{CRBN} E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica, 2020, 105, e237-e241.	1.7	41
3	Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM. Blood Advances, 2021, 5, 3794-3798.	2.5	30
4	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood, 2021, 138, 1721-1726.	0.6	25
5	Allele-specific methylation of imprinted genes in fetal cord blood is influenced by cis-acting genetic variants and parental factors. Epigenomics, 2018, 10, 1315-1326.	1.0	20
6	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Communications Biology, 2021, 4, 799.	2.0	16
7	Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutationâ€negative earlyâ€onset and highâ€risk breast cancer patients. International Journal of Cancer, 2018, 143, 1416-1425.	2.3	15
8	Hypermethylation of the non-imprinted maternal MEG3 and paternal MEST alleles is highly variable among normal individuals. PLoS ONE, 2017, 12, e0184030.	1.1	12
9	Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma. Blood, 2019, 134, 4349-4349.	0.6	4
10	RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia. Blood, 2019, 134, 1277-1277.	0.6	1
11	Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation. Blood, 2018, 132, 404-404.	0.6	0
12	Clonal Competition Models to Understand Progression and Resistance in Myeloma. Blood, 2019, 134, 1807-1807.	0.6	0
13	High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence. Blood, 2021, 138, 818-818.	0.6	0